Renaissance Technologies
CTSO icon

Renaissance Technologies’s Cytosorbents Corp CTSO Stock Holding History

Renaissance Technologies’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.4K Sell
100,020
-700
-0.7% -$370 ﹤0.01% 3065
2026
Q1 		$57K Buy
100,720
+600
+0.6% +$410 ﹤0.01% 3099
2025
Q4 		$64K Sell
100,120
-34,685
-26% -$26.7K ﹤0.01% 3066
2025
Q3 		$126K Buy
134,805
+18,166
+16% +$17.9K ﹤0.01% 3225
2025
Q2 		$149K Sell
116,639
-108,615
-48% -$109K ﹤0.01% 3230
2025
Q1 		$225K Buy
225,254
+137,234
+156% +$145K ﹤0.01% 3044
2024
Q4 		$80.1K Buy
88,020
+8,400
+11% +$8.24K ﹤0.01% 3318
2024
Q3 		$119K Buy
79,620
+3,800
+5% +$4.17K ﹤0.01% 3229
2024
Q2 		$53.3K Sell
75,820
-3,800
-5% -$3.3K ﹤0.01% 3283
2024
Q1 		$76K Sell
79,620
-95,700
-55% -$93.1K ﹤0.01% 3417
2023
Q4 		$195K Buy
175,320
+56,220
+47% +$83.5K ﹤0.01% 3141
2023
Q3 		$224K Buy
119,100
+200
+0.2% +$574 ﹤0.01% 3048
2023
Q2 		$427K Buy
118,900
+300
+0.3% +$949 ﹤0.01% 2959
2023
Q1 		$400K Buy
118,600
+200
+0.2% +$600 ﹤0.01% 2992
2022
Q4 		$184K Sell
118,400
-79,396
-40% -$118K ﹤0.01% 3446
2022
Q3 		$269K Buy
197,796
+57,676
+41% +$113K ﹤0.01% 3256
2022
Q2 		$307K Buy
140,120
+55,220
+65% +$127K ﹤0.01% 3447
2022
Q1 		$271K Buy
+84,900
New +$304K ﹤0.01% 3514
2021
Q3 		– Sell
-140,100
Closed -$1.06M – 3531
2021
Q2 		$1.06M Sell
140,100
-39,900
-22% -$336K ﹤0.01% 2640
2021
Q1 		$1.56M Buy
180,000
+106,900
+146% +$1.02M ﹤0.01% 2379
2020
Q4 		$583K Sell
73,100
-22,900
-24% -$192K ﹤0.01% 2751
2020
Q3 		$766K Buy
+96,000
New +$866K ﹤0.01% 2644
2019
Q2 		– Sell
-38,800
Closed -$294K – 3571
2019
Q1 		$294K Sell
38,800
-82,900
-68% -$646K ﹤0.01% 3100
2018
Q4 		$983K Buy
+121,700
New +$1.21M ﹤0.01% 2577
2018
Q3 		– Sell
-230,300
Closed -$2.63M – 3372
2018
Q2 		$2.63M Buy
+230,300
New +$2.18M ﹤0.01% 2131

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Renaissance Technologies's CTSO Position: Q2 2026 in Review

Renaissance Technologies reduced its Cytosorbents Corp (CTSO) stake by 0.69% in Q2 2026, selling an estimated $370 and leaving 100,020 shares worth $37.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3065.

Renaissance Technologies first reported a position in CTSO in Q2 2018 and has held it in 25 quarters since. The position peaked at $2.63M in Q2 2018. 42 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.

  • Renaissance Technologies held 100,020 shares of Cytosorbents Corp worth $37.4K as of Q2 2026.
  • Renaissance Technologies sold 700 Cytosorbents Corp shares in Q2 2026, an estimated $370.
  • Cytosorbents Corp made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3065 holding.
  • Renaissance Technologies first reported a position in Cytosorbents Corp in Q2 2018 and has held it in 25 quarters since.
  • Renaissance Technologies's Cytosorbents Corp position peaked at $2.63M in Q2 2018.
  • 42 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.